Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic
Tags :BridgeBio Pharma
BridgeBio Pharma, through its affiliate QED Therapeutics, and Helsinn Group announced a global collaboration and licensing agreement to further develop and commercialize QED Therapeutics’ FGFR1-3 inhibitor, infigratinib, in oncology and all other indications except
